COVID-19 – BioTuesdays

Developments

Soricimed to investigate SOR-C13 to treat COVID-19

Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...

December 17, 2020

Developments

Capricor initiates dosing in Phase 2 COVID-19 trial

Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...

November 24, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Developments

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

Hepion Pharmaceuticals (NASDAQ:HEPA) will present virtually at the Roth Capital “therapeutic approaches for COVID-19” event taking place on Oct. 28 from 9:00 am to 1:20 pm ET; and at the B. Riley Securities...

October 26, 2020

Developments

PhaseBio discontinues Phase 2 COVID-19 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) discontinued its Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of vasoactive intestinal peptide...

October 23, 2020

Developments

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patients in its Phase 2 trial evaluating fostamatinib for the treatment of hospitalized COVID-19 patients. The study is sponsored by the NIH’s National Heart, Lung...

October 9, 2020

Features

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Developments

Enlivex posts positive COVID-19 results in severe/critical patients

Enlivex Therapeutics (NASDAQ:ENLV) reported positive topline results of an investigator-initiated clinical trial of Allocetra in five COVID-19 patients, three of which were in severe condition and two in critical...

October 1, 2020

Features

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Tag - COVID-19

Soricimed to investigate SOR-C13 to treat COVID-19

Capricor initiates dosing in Phase 2 COVID-19 trial

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Hepion to present on therapeutic approaches to COVID-19; NASH at Oct. 28; Oct. 29 events

PhaseBio discontinues Phase 2 COVID-19 trial

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Monopar Therapeutics readies two key clinical trials in fourth quarter

Enlivex posts positive COVID-19 results in severe/critical patients

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter